Galapagos NV (ADR) (NASDAQ: GLPG) is off to an incredibly strong start in the market today, and for good reason. The company published results from a Phase 2a clinical trial, causing excitement among investors and sending the value of the stock toward the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:33), GLPG is trading at $82.44 per share after a gain of $9.27 per share or 12.67% thus far today.
GLPG Gains On Clinical Data
As mentioned above, Galapagos is having a strong start to the trading session today after posting positive results from a Phase 2a clinical trial. The trial, known as FLORA, assessed the autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis, also known as PIF. Here are the key points from the clinical results...
- Forced Vital Capacity – GLPG said that forced vital capacity, or FVC, in the lungs stabilized over the 12-week treatment period. On the placebo arm, patients showed an expected decline in FVC.
- Functional Respiratory Imaging – The company also said that functional respiratory imaging, also know as FRI, has confirmed the FVC data with statistical significance.
- Tolerability – GLPG said that the treatment proved to be generally well tolerated through the clinical study.
- First In Class – This study has been the first patient trial in which an autotaxin inhibitor has shown an effect in the IPF patient population.
- Progression – Galapagos expects that GLPG1690 will progress to a late stage clinical trial considering the positive results.
In a statement, Dr. Toby Maher, Professor of Interstitial Lung Disease at Imperial College in London and Consultant Physician at Royal Brompton Hospital in London, had the following to offer with regard to the GLPG clinical study...
“Galapagos' results with GLPG1690 are extremely exciting and exceed those of previous studies. This brings hope to patients with idiopathic pulmonary fibrosis that new effective treatment may be on the horizon. Importantly, some patients even showed an increase of lung function with only 12 weeks of treatment, and the drug was well tolerated. The results from FLORA beg the question how patients will fare with longer treatment. I urge Galapagos and the IPF community to progress to the next phase of clinical trials as rapidly as possible...”
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We'll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on GLPG. In particular, we're interested in following the ongoing work with regard to GLPG1960, and considering the data that has already been released, we are excited to see this thing progress. Nonetheless, we'll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!